From the outset, the company has used a niche strategy in which it targets value-added market segments and offers top-quality, unique and innovative products to healthcare professionals (haemodialysis machines, catheter locking solutions and chronic and acute haemodialysis equipment) in order to meet patients' needs.
In the 20 years Théradial has been in the market, it has developed lasting relationships of trust with the entire medical community and with healthcare facilities, providing its manufacturing partners with special, privileged access to the French dialysis market.
Over the years, Théradial has shown its ability to consistently pinpoint market opportunities in order to expand its product portfolio and maintain steady growth.
Because Théradial acquired the French status of pharmaceutical establishment in 2014, which enabled the company to sell products requiring marketing authorisation, its presence in the growing home-dialysis segment and the fact that it now targets dialysis as well as other specialisations (oncology, gastroenterology, etc.) will drive the company's future growth.
The transaction and choice of investors favouring expert funds in the healthcare industry demonstrate the company's desire to transfer capital and receive assistance, as well as increase its resources to enable it to maintain and even accelerate its growth.
Frédéric Le Pottier, who has worked for the company for a decade, will oversee the transaction. The founding shareholder, Bruno Duval, will become chairman of the supervisory board and will remain a major shareholder.
Advisory services to the founding shareholder of Théradial
Edmond de Rothschild Corporate Finance - M&A: Philippe Flament (Associate Director), Sébastien Auger (Executive Director), Mohamed Rtel Bennani (Analyst)
Edmond de Rothschild Corporate Finance - Financing Advisory: Grégory Fradelizi (Associate Director)